Theravance Biopharma, Inc. - stock earnings
TBPH Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -8.5 million USD | 17.6 million USD |
| 2023Q3 | -9.0 million USD | 15.7 million USD |
| 2023Q2 | -15.6 million USD | 13.7 million USD |
| 2023Q1 | -22.1 million USD | 10.4 million USD |
| 2022Q4 | -14.3 million USD | 14.6 million USD |
| 2022Q3 | 916.6 million USD | 12.5 million USD |
| 2022Q2 | -8.2 million USD | 11.1 million USD |
| 2022Q1 | -25.9 million USD | 13.2 million USD |
| 2021Q4 | -32.0 million USD | 14.9 million USD |
| 2021Q3 | -35.3 million USD | 13.2 million USD |
| 2021Q2 | -52.4 million USD | 12.9 million USD |
| 2021Q1 | -79.7 million USD | 14.3 million USD |
| 2020Q4 | -58.4 million USD | 18.7 million USD |
| 2020Q3 | -73.6 million USD | 18.3 million USD |
| 2020Q2 | -62.9 million USD | 15.0 million USD |
| 2020Q1 | -83.1 million USD | 19.9 million USD |
| 2019Q4 | -65.6 million USD | 29.5 million USD |
| 2019Q3 | -58.4 million USD | 12.4 million USD |
| 2019Q2 | -39.8 million USD | 26.2 million USD |
| 2019Q1 | -72.6 million USD | 5.3 million USD |
| 2018Q4 | -50.2 million USD | 15.7 million USD |
| 2018Q3 | -59.4 million USD | 12.8 million USD |
| 2018Q2 | -40.8 million USD | 23.5 million USD |
| 2018Q1 | -65.1 million USD | 8.3 million USD |
| 2017Q4 | -86.9 million USD | 4.5 million USD |
| 2017Q3 | -66.9 million USD | 4.3 million USD |
| 2017Q2 | -66.3 million USD | 3.5 million USD |
| 2017Q1 | -65.3 million USD | 3.1 million USD |
| 2016Q4 | -67.3 million USD | 5.7 million USD |
| 2016Q3 | -34.0 million USD | 19.1 million USD |
| 2016Q2 | -47.2 million USD | 5.5 million USD |
| 2016Q1 | -42.2 million USD | 18.4 million USD |
| 2015Q4 | -44.8 million USD | 3.9 million USD |
| 2015Q3 | -47.3 million USD | 10.7 million USD |
| 2015Q2 | -47.6 million USD | 7.1 million USD |
| 2015Q1 | -42.5 million USD | 20.4 million USD |
| 2014Q4 | -64.3 million USD | 1.4 million USD |
| 2014Q3 | -54.5 million USD | 6.3 million USD |
| 2014Q2 | -58.2 million USD | 3.0 million USD |
| 2014Q1 | -60.0 million USD | 945000 USD |
| 2013Q4 | -44.1 million USD | 175000 USD |
| 2013Q3 | -41.1 million USD | 24000 USD |
| 2013Q2 | -39.0 million USD | 5000 USD |
| 2013Q1 | -32.2 million USD | 22000 USD |
| 2012Q4 | ? USD | 4.5 million USD |
| 2012Q2 | -87.0 million USD | 125.7 million USD |
| 2012Q1 | 87.0 million USD | 125.7 million USD |
TBPH Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -55.2 million USD | 57.4 million USD |
| 2022 | -92.8 million USD | 51.3 million USD |
| 2021 | -199.4 million USD | 55.3 million USD |
| 2020 | -278.0 million USD | 71.9 million USD |
| 2019 | -236.5 million USD | 73.4 million USD |
| 2018 | -215.5 million USD | 60.4 million USD |
| 2017 | -285.4 million USD | 15.4 million USD |
| 2016 | -190.7 million USD | 48.6 million USD |
| 2015 | -182.2 million USD | 42.1 million USD |
| 2014 | -237.0 million USD | 11.7 million USD |
| 2013 | -156.3 million USD | 226000 USD |
| 2012 | -9.6 million USD | 130.1 million USD |
TBPH
Price: $9.46
52 week price:
Earnings Per Share: -1.00 USD
P/E Ratio: -8.64
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 260600
Ebitda: -62.9 millionMarket Capitalization: 450.8 million